Please assess the completion status of the following clinical trial:

Trial Title: Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent~* Measurable Disease~* Eastern Cooperative Oncology Group (ECOG) 0 or 1~* Lab / imaging requirements~* Neg for Human Immunodeficiency Virus (HIV), Hepatitis B (HepB), C~* Men and Women \> 18 years (16 were allowable)~* Prior therapy restriction (adjuvant only)~Exclusion:~* Pregnant / nursing~* Inadequate contraception~* Brain metastasis~* Primary ocular or mucosal melanoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Ipilimumab and Dacarbazine (Type: EXPERIMENTAL): In Maintenance phase: Ipilimumab will be continued. Dacarbazine was given up to Week 22 and is not given in the Maintenance phase
- Arm B: Placebo and Dacarbazine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).